Listing 1 - 4 of 4 |
Sort by
|
Choose an application
Cervical cancer is the second most common form of cancer found in women and it is responsible for more than a quarter of a million deaths worldwide each year. With approximately 70% of cervical cancers now known to be caused by two types of the human papilloma virus (HPV), there is great interest surrounding the approval of the first preventative vaccines for clinical use. Despite this excitement, many questions remain about how the new vaccines should best be implemented and how cervical cancer screening will change following vaccination.Part of the Oxford Oncology Library series, this practice
Cervix uteri --- Cancer vaccines. --- Oncologic vaccines --- Oncology vaccines --- Neoplasm vaccines --- Tumor vaccines --- Vaccines --- Cancer --- Prevention.
Choose an application
Rapid progress in the definition of tumour antigens, and improved immunisation methods, bring effective cancer vaccines within reach. In this wide-ranging survey, clinicians and scientists at the forefront of these developments review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, chapters cover the rationale, development and implementation of vaccines in human cancers generally, and with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. Target identification, delivery vectors and clinical trial design are reviewed, and the book begins and ends with lucid overviews from the editors, including the most recent developments. Encapsulating recent scientific progress and the likely clinical potential of cancer vaccines, this book provides an essential introduction and guide for oncologists, immunologists and indeed all clinicians treating cancer patients.
Cancer vaccines. --- Cancer --- Immunotherapy.
Choose an application
Choose an application
Listing 1 - 4 of 4 |
Sort by
|